- Home
- CIK vs CHRS Comparison
CIK vs CHRS Comparison
Compare CIK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- CHRS
- Stock Information
- Founded
- CIK 1987
- CHRS 2010
- Country
- CIK United States
- CHRS United States
- Employees
- CIK N/A
- CHRS N/A
- Industry
- CIK Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIK Finance
- CHRS Health Care
- Exchange
- CIK Nasdaq
- CHRS Nasdaq
- Market Cap
- CIK 163.1M
- CHRS 194.1M
- IPO Year
- CIK N/A
- CHRS 2014
- Fundamental
- Price
- CIK $2.84
- CHRS $1.79
- Analyst Decision
- CIK
- CHRS Strong Buy
- Analyst Count
- CIK 0
- CHRS 4
- Target Price
- CIK N/A
- CHRS $4.51
- AVG Volume (30 Days)
- CIK 115.4K
- CHRS 1.2M
- Earning Date
- CIK 01-01-0001
- CHRS 11-05-2025
- Dividend Yield
- CIK 9.03%
- CHRS N/A
- EPS Growth
- CIK N/A
- CHRS N/A
- EPS
- CIK N/A
- CHRS 1.55
- Revenue
- CIK N/A
- CHRS $272,209,000.00
- Revenue This Year
- CIK N/A
- CHRS N/A
- Revenue Next Year
- CIK N/A
- CHRS $109.48
- P/E Ratio
- CIK N/A
- CHRS $3.23
- Revenue Growth
- CIK N/A
- CHRS 52.33
- 52 Week Low
- CIK $2.50
- CHRS $0.66
- 52 Week High
- CIK $3.19
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- CIK 25.43
- CHRS 61.21
- Support Level
- CIK $2.82
- CHRS $1.63
- Resistance Level
- CIK $2.99
- CHRS $1.85
- Average True Range (ATR)
- CIK 0.03
- CHRS 0.11
- MACD
- CIK -0.01
- CHRS -0.02
- Stochastic Oscillator
- CIK 8.82
- CHRS 65.15
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.